RT Journal Article
SR Electronic
T1 Effects of basiliximab and triple therapy on airway mucociliary clearance of rats
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P2462
VO 44
IS Suppl 58
A1 Aristides Tadeu Correia
A1 Francine Maria Almeida
A1 Afonso da Silva Alves Bento
A1 Hugo Kenji Matsushima Hirano
A1 Paulo Manuel Pêgo-Fernandes
A1 Rogerio Pazetti
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/P2462.abstract
AB Previous studies showed that immunosuppressive drugs impaired mucociliary clearance of rats. Basiliximab has been used as induction therapy before lung transplantation in many centers around the world. However, there are few studies reporting its side effects. Due to its high specificity and mild effects, we believe that basiliximab has no effect on mucociliary apparatus. Forty male Wistar rats were divided in 4 groups: Control (tap water); Basiliximab, Triple Therapy (tacrolimus, mycophenolate and prednisone), and Basiliximab+Triple Therapy. Drugs were administered by gavage daily for 7 days. After this period, ciliary beating frequency (CBF) and mucociliary transport velocity (MCTV) were measured. There was no difference amoung group concerning CBF. However, MCTV was lower in Basiliximab (0.87±0.21 mm/min) and Basiliximab+Triple Therapy (0.80±0.28 mm/min) in comparison with Control (1.28±0.21 mm/min) and Triple Therapy (1.17±0.20 mm/min) (p<0.05). Basiliximab impaired mucociliary clearance by diminishing MCTV.